Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston
3
×
boston blog main
boston top stories
eli lilly
3
×
life sciences
national blog main
national top stories
3
×
san francisco blog main
san francisco top stories
avapritinib
blueprint medicines
clinical trials
deals
genentech
indiana blog main
indiana top stories
medullary thyroid cancer
non-small cell lung cancer
pralsetinib
roche
selpercatinib
thyroid cancer
alexion pharmaceuticals
alnylam pharmaceutials
arrowhead pharmaceuticals
boehringer ingelheim
cancer
cancer drugs
capmatinib
cstone pharmaceuticals
dicerna pharmaceuticals
europe blog main
europe top stories
european medicines agency
fda
fisogatinib
flatiron health
gastrointestinal stromal tumors
hepatitis b
What
medicines
approval
blueprint
cancer
drug
fda
ret
abandoning
address
ago
approves
baggage
candidate
carries
certain
companies
currently
cuts
deal
designed
development
dicerna
free
genetic
gets
interference
latest
long
marketing
muscle
pact
pass
pharma
regulatory
review
rna
rnai
roche
signature
signatures
Language
unset
Current search:
boston
×
" eli lilly "
×
" national top stories "
×
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
5 years ago
Free of Baggage, Dicerna Cuts Another RNAi Deal and Gets $200M